Therapeutic potential of interleukin 1 inhibitors in the treatment of alcoholic liver disease
Stephanie Mathews, Bin Gao – 22 April 2013
Cracking the ENCODE: From transcription to therapeutics
Gautam Mehta, Rajiv Jalan, Rajeshwar P Mookerjee – 22 April 2013
Emergent nonconventional mesosystemic shunt for diffuse portomesenteric thrombosis: Sparing patients from liver/multivisceral transplantation
Shunji Nagai, Marwan S. Abouljoud, Marwan Kazimi, Atsushi Yoshida – 13 April 2013
Long‐term follow‐up of endoscopic therapy for stenosis of the biliobiliary anastomosis associated with orthotopic liver transplantation
Jörg G. Albert, Natalie Filmann, Julia Elsner, Christian Moench, Jörg Trojan, Jörg Bojunga, Christoph Sarrazin, Mireen Friedrich‐Rust, Eva Herrmann, Wolf Otto Bechstein, Stefan Zeuzem, Wolf Peter Hofmann – 13 April 2013 – Endoscopic treatment for stenosis of an anastomotic biliary stricture (ABS) after orthotopic liver transplantation (OLT) has been proven to be effective and safe, but the long‐term outcomes and the risk factors for recurrence are unknown. All 374 patients who underwent OLT at Frankfurt University Hospital were screened for the occurrence of ABSs.
Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates: An analysis of cutoff values
Sarah Raevens, Isabelle Colle, Koen Reyntjens, Anja Geerts, Frederik Berrevoet, Xavier Rogiers, Roberto I. Troisi, Hans Vlierberghe, Michel Pauw – 13 April 2013 – Portopulmonary hypertension (POPH), a complication of chronic liver disease, may be a contraindication to liver transplantation (LT) because of the elevated risk of peritransplant and posttransplant morbidity and mortality. Because POPH is frequently asymptomatic, screening with echocardiography is recommended. The only reliable technique, however, for diagnosing POPH is right heart catheterization (RHC).
In Memoriam: David Hull, M.D.
Angel E. Alsina, John McNab – 13 April 2013
False positivity for the human immunodeficiency virus antibody after influenza Vaccination in a living donor for liver transplantation
Susumu Eguchi, Mitsuhisa Takatsuki, Akihiko Soyama, Yasuhiro Torashima, Ayumi Tsuji, Tamotsu Kuroki – 9 April 2013
Reply
Roongruedee Chaiteerakij, William S. Harmsen, Euijung Ryu, Rosebud O. Roberts, Janet E. Olson, Terry M. Therneau, Lewis R. Roberts – 8 April 2013
Intrahepatic cholestasis of pregnancy and associated hepatobiliary disease: A population‐based cohort study
Hanns‐Ulrich Marschall, Elisabeth Wikström Shemer, Jonas F. Ludvigsson, Olof Stephansson – 8 April 2013 – Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease in pregnancy. We aimed to estimate the risk of developing hepatobiliary disease in women with ICP and the odds of developing ICP in women with prevalent hepatobiliary disease. We analyzed data of women with births between 1973 and 2009 and registered in the Swedish Medical Birth Register.
IL‐25 prevents and cures fulminant hepatitis in mice through a myeloid‐derived suppressor cell‐dependent mechanism
Massimiliano Sarra, Maria Laura Cupi, Roberta Bernardini, Giulia Ronchetti, Ivan Monteleone, Marco Ranalli, Eleonora Franzè, Angelamaria Rizzo, Alfredo Colantoni, Flavio Caprioli, Marco Maggioni, Alessandra Gambacurta, Maurizio Mattei, Thomas T. Macdonald, Francesco Pallone, Giovanni Monteleone – 8 April 2013 – Fulminant hepatitis (FH) is a disease characterized by massive destruction of hepatocytes with severe impairment of liver function.